Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-017760
Filing Date
2023-11-06
Accepted
2023-11-06 16:10:34
Documents
78
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q eqrx-20230930x10q.htm   iXBRL 10-Q 2029817
2 EX-31.1 eqrx-20230930xex31d1.htm EX-31.1 18573
3 EX-32.1 eqrx-20230930xex32d1.htm EX-32.1 9603
  Complete submission text file 0001558370-23-017760.txt   8719206

Data Files

Seq Description Document Type Size
4 EX-101.SCH eqrx-20230930.xsd EX-101.SCH 50524
5 EX-101.CAL eqrx-20230930_cal.xml EX-101.CAL 47455
6 EX-101.DEF eqrx-20230930_def.xml EX-101.DEF 245928
7 EX-101.LAB eqrx-20230930_lab.xml EX-101.LAB 459864
8 EX-101.PRE eqrx-20230930_pre.xml EX-101.PRE 400670
72 EXTRACTED XBRL INSTANCE DOCUMENT eqrx-20230930x10q_htm.xml XML 1716263
Mailing Address 50 HAMPSHIRE STREET CAMBRIDGE MA 02139
Business Address 50 HAMPSHIRE STREET CAMBRIDGE MA 02139 (617) 315-2255
EQRx, Inc. (Filer) CIK: 0001843762 (see all company filings)

EIN.: 861691173 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40312 | Film No.: 231380071
SIC: 2834 Pharmaceutical Preparations